Aspirin (Propan Aspirin, Soluble Aspirin, Aquaprin Junior, Aquaprin, Aspasol, Aspasol Junior, Aspirin (Green)_, Aspirin, Wills Aspirin, Endoflam)
Aspirin
The Premier Pharmaceutical Co Ltd
Every registration of this product has been cancelled.
Registration
- Applicant
- The Premier Pharmaceutical Co Ltd
- Registrations
- 11
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Propan aspirin TABLET ASPIRIN 300 MG | Not listed | B0741B/2.7/741 | Cancelled | Not determined | None |
| Soluble aspirin tablets 300 MG TABLET ASPIRIN 300 MG | 300 mgTablets | B0742B/2.7/742 | Cancelled | Not determined | None |
| Aquaprin junior tablets TABLET ASPIRIN 75 MG | Tablets | B1222B/2.7/1222 | Cancelled | Not determined | None |
| Aquaprin tablets TABLET ASPIRIN 300 MG | Tablets | B1223B/2.7/1223 | Cancelled | Not determined | None |
| Aspasol tablets TABLET ASPIRIN A 300 MG | Tablets | B1279 | Cancelled | Not determined | None |
| Aspasol junior tablets TABLET ASPIRIN A 75 MG | Tablets | B1280 | Cancelled | Not determined | None |
| Aspirin tablets (green)_ TABLET ASPIRIN 300 MG | Tablets | B1416B/2.7/1416 | Cancelled | Not determined | None |
| Aspirin tablets 300 MG TABLET ASPIRIN A 300 MG | 300 MGTablets | B1455 | Cancelled | Not determined | None |
| Wills aspirin* EACH TABLET CONTAINS ASPIRIN 300,0 mg | Not listed | D0007D/2.7/7 | Cancelled | Not determined | None |
| Aspirin 500 mg* EACH TABLET CONTAINS ASPIRIN 500 mg | 500 mg | E0219E/2.8/219 | Cancelled | Not determined | None |
| Endoflam tablets* EACH TABLET CONTAINS ASPIRIN (MICROENCAPSULATED) EQUIVALENT TO ASPIRIN 600 mg | Tablets | H0228H/2.8/228 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S2: Aspirin
- the treatment of children or adolescents; and
- the prophylaxis of cardiovascular disease in adults (S0)
Consolidated Schedules 06 July 2026, lines 1616 to 1620
5 of 7 approved products with this ingredient carry S3 on their leaflet.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.